Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

$180M+ Sales Milestone Deal: Ocugen Partners with Korean Pharma Giant for Breakthrough Eye Gene Therapy

Summary by stocktitan.net
Ocugen licenses OCU400 gene therapy for retinitis pigmentosa to Kwangdong Pharma, including $7.5M upfront, $180M+ in milestones, and 25% royalties. Phase 3 BLA filing targeted for 2026.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

4 Articles

modernretina.commodernretina.com

Ocugen, Kwangdong complete licensing agreement for OCU400 gene therapy in Korea

Kwangdong, a top 5 pharmaceutical and healthcare company in Korea, is actively involved in research and development innovation, including “transformational late-stage, high-impact technologies.”

Read Full Article
channelchek.comchannelchek.com

Release - Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - Channelchek

Open the article to view the coverage from channelchek.com

Read Full Article
ophthalmologytimes.comophthalmologytimes.com

Ocugen and Kwangdong complete licensing agreement for OCU400 gene therapy in Korea

Kwangdong, a top 5 pharmaceutical and healthcare company in Korea, is actively involved in research and development innovation, including “transformational late-stage, high-impact technologies.”

Read Full Article
stocktitan.netstocktitan.net

$180M+ Sales Milestone Deal: Ocugen Partners with Korean Pharma Giant for Breakthrough Eye Gene Therapy

Ocugen licenses OCU400 gene therapy for retinitis pigmentosa to Kwangdong Pharma, including $7.5M upfront, $180M+ in milestones, and 25% royalties. Phase 3 BLA filing targeted for 2026.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Monday, September 15, 2025.
Sources are mostly out of (0)

Similar News Topics

Innovation icon

Innovation

South Korea icon

South Korea

News
For You
SearchBlindspotLocal